NEMUS Bioscience and Catalent to Advance NB1222 in

COSTA MESA, CA--(Marketwired - Mar 3, 2017) - NEMUS Bioscience, Inc. ( OTCQB : NMUS ) today announced that the company is moving forward with Catalent Pharma Solutions (Catalent) to advance development of a human-dosage suppository formulation of NB1222, the proprietary prodrug of tetrahydrocannabinol (THC). NB1222, also known as the prodrug THC-valine-hemisuccinate, is being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222 is synthetically manufactured and is not plant-derived.

"Nemus is looking forward to working with Catalent to complete this important milestone as the company prepares to advance the candidate therapy to human clinical trials," stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. "In addition to the recognized anti-emetic activity of cannabinoids, we feel a formulation that could provide reliable and predictable bioavailability and pharmacokinetics, could leverage other valuable physiological attributes associated with cannabinoids like appetite stimulation along with anxiolytic and pain mitigation properties in a patient population that could benefit from these activities."

Dr. Aris Gennadios, President, Catalent Softgel Technologies commented, "We believe Catalent's softgel technology is a great delivery choice for NB1222. With the convenience that softgel can offer, combined with a lipid formulation to enhance bioavailability and help assure dose uniformity, we expect Nemus to be well positioned to pursue development of an efficacious drug product."

"The global CINV market is a multi-billion dollar opportunity with projected growth as populations live longer, increasing the likelihood of developing a malignancy over time," commented Dr. Murphy. "THC-val-HS now has a patent footprint in major markets worldwide and we look forward to also advancing this prodrug into formulation activity for the glaucoma indication using our candidate molecule, NB1111."

FORWARD LOOKING STATEMENT This press release contains forward-looking statements, including statements about the studies relating to and the potential benefits of NB1111 and NB1222 as well as the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "expects," "plans," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

ABOUT CATALENT PHARMA SOLUTIONS

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

ABOUT NEMUS BIOSCIENCE, INC.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting potential adverse events. NEMUS's strategy is to explore the use of natural and synthetic compounds, alone or in combination with partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit http://www.nemusbioscience.com .